Reported Earnings • Mar 17
Full year 2025 earnings released: ₩283 loss per share (vs ₩79.00 loss in FY 2024) Full year 2025 results: ₩283 loss per share (further deteriorated from ₩79.00 loss in FY 2024). Revenue: ₩5.74b (down 11% from FY 2024). Net loss: ₩8.96b (loss widened 246% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. New Risk • Feb 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 59% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩5.6b revenue, or US$3.9m). Market cap is less than US$100m (₩141.5b market cap, or US$99.2m). Announcement • Jan 30
iNtRON Biotechnology, Inc., Annual General Meeting, Mar 19, 2026 iNtRON Biotechnology, Inc., Annual General Meeting, Mar 19, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 137, sagimakgol-ro, jungwon-gu, gyeonggi-do, seongnam South Korea